A Phase II study (SPARK, NCT03318523) evaluated the effects of the monoclonal antibody BIIB054 (trade name Cinpanemab), which targeted aggregated forms of α-synuclein in participants with PD. The gene discussed is SNCA; the disease is Parkinson disease.